Malaria Vaccine Breakthroughs: Transforming Africa's Health Landscape
カートのアイテムが多すぎます
ご購入は五十タイトルがカートに入っている場合のみです。
カートに追加できませんでした。
しばらく経ってから再度お試しください。
ウィッシュリストに追加できませんでした。
しばらく経ってから再度お試しください。
ほしい物リストの削除に失敗しました。
しばらく経ってから再度お試しください。
ポッドキャストのフォローに失敗しました
ポッドキャストのフォロー解除に失敗しました
Malaria Vaccine Breakthroughs: Transforming Africa's Health Landscape
-
ナレーター：
-
著者：
このコンテンツについて
As of early April 2025, 19 African countries, including Benin, Burkina Faso, Burundi, Cameroon, and others, have integrated either the RTS,S or R21 malaria vaccines into their childhood immunization programs and national malaria control strategies. This widespread adoption is a result of the World Health Organization's (WHO) prequalification of these vaccines, ensuring their safety and quality. The RTS,S vaccine was prequalified in July 2022, while the R21 vaccine received prequalification in December 2023[5].
One of the most notable recent initiatives is Uganda's launch of the largest malaria vaccine introduction to date. The R21/Matrix-M malaria vaccine, which is administered in four doses at 6, 7, 8, and 18 months, is initially targeting 1.1 million children under the age of two. This effort underscores the commitment to protecting young children, who are among the most vulnerable to malaria[1].
Mali has also made significant strides, becoming the 20th African country to introduce the malaria vaccine on World Malaria Day in April 2025. The introduction of the vaccine in Mali is supported by UNICEF, which is engaging in community outreach and using digital tools to promote vaccination and counter misinformation. This initiative follows a successful pilot evaluation of the RTS,S/AS01 malaria vaccine in Ghana, Kenya, and Malawi, which resulted in a 13% reduction in mortality among age-eligible children between 2019 and 2023[3].
Despite these advancements, there are also challenges in the development of new malaria vaccines. For instance, the FDA has paused BioNTech's phase 1/2a trial of its experimental malaria vaccine, BNT165e, due to unspecified concerns. This pause highlights the rigorous scrutiny and safety protocols in place for vaccine development[4].
The demand for malaria vaccines remains high, with at least 30 African countries planning to introduce these vaccines into their immunization programs. The availability of two safe and effective vaccines, RTS,S and R21, ensures sufficient supply to meet this demand, providing a powerful tool in the ongoing battle against malaria[5].
These recent developments mark a critical milestone in public health, offering new hope for reducing the burden of malaria, especially among children in high-risk areas. As more countries scale up their vaccination efforts, the impact on malaria-related mortality and morbidity is expected to be significant.